Nebula Research & Development LLC Has $1.60 Million Stock Holdings in Balchem Co. (NASDAQ:BCPC)

Nebula Research & Development LLC lifted its stake in shares of Balchem Co. (NASDAQ:BCPC - Free Report) by 31.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,837 shares of the basic materials company's stock after purchasing an additional 2,328 shares during the period. Nebula Research & Development LLC's holdings in Balchem were worth $1,603,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. lifted its holdings in Balchem by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,961,487 shares of the basic materials company's stock worth $645,703,000 after buying an additional 42,693 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Balchem by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 938,504 shares of the basic materials company's stock valued at $153,000,000 after acquiring an additional 9,600 shares during the last quarter. Geneva Capital Management LLC increased its position in Balchem by 5.1% in the fourth quarter. Geneva Capital Management LLC now owns 819,746 shares of the basic materials company's stock worth $133,615,000 after purchasing an additional 39,877 shares during the period. FMR LLC raised its holdings in Balchem by 16.0% during the 4th quarter. FMR LLC now owns 576,994 shares of the basic materials company's stock worth $94,047,000 after purchasing an additional 79,499 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of Balchem by 11.0% during the 4th quarter. JPMorgan Chase & Co. now owns 509,490 shares of the basic materials company's stock worth $83,044,000 after buying an additional 50,504 shares during the period. 87.91% of the stock is owned by institutional investors.

Balchem Stock Down 0.3 %

Shares of Balchem stock traded down $0.45 on Thursday, hitting $156.11. The company had a trading volume of 65,622 shares, compared to its average volume of 133,567. Balchem Co. has a twelve month low of $141.09 and a twelve month high of $186.03. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.99 and a quick ratio of 1.16. The stock has a 50-day moving average of $163.69 and a 200-day moving average of $166.87. The firm has a market capitalization of $5.08 billion, a P/E ratio of 39.73, a P/E/G ratio of 4.41 and a beta of 0.75.

Balchem (NASDAQ:BCPC - Get Free Report) last posted its quarterly earnings data on Thursday, April 24th. The basic materials company reported $1.22 earnings per share for the quarter, missing the consensus estimate of $1.25 by ($0.03). Balchem had a return on equity of 11.37% and a net margin of 13.47%. The firm had revenue of $250.52 million for the quarter, compared to analyst estimates of $245.70 million. During the same period in the prior year, the company earned $1.03 earnings per share. The firm's quarterly revenue was up 4.5% on a year-over-year basis. Research analysts predict that Balchem Co. will post 4.64 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on BCPC. HC Wainwright set a $180.00 target price on shares of Balchem and gave the stock a "buy" rating in a report on Monday. StockNews.com lowered shares of Balchem from a "buy" rating to a "hold" rating in a report on Tuesday, February 25th. Finally, Sidoti upgraded Balchem to a "hold" rating in a report on Tuesday, February 25th.

Balchem Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.